Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will examine the safety of ascending doses of AB-SA01 when topically applied to intact skin of healthy adults.
Full description
AB-SA01 consists of three bacteriophages (viruses) that target Staphylococcus aureus bacteria.
The safety of AB-SA01 will be assessed when topically administered once daily to the volar aspect of the forearm at a dose of 10^8 plaque forming units (PFU) per phage for 3 consecutive days, and then at a dose of 10^9 plaque forming units (PFU) per phage for 3 consecutive days. Both AB-SA01 and placebo will be administered to each subject to provide his/her own control for evaluation of skin reactions. The right or left placement of the placebo will be randomized and double-blinded.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
12 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal